Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA)   11

Background
The Biomedical Advanced Research and Development Authority (BARDA) was established within the U.S. Government to catalyze innovation in advanced research and development (R&D), manufacturing, and procurement of Medical Countermeasures (MCMs) to protect people during public health emergencies from threats such as chemical, biological, radiological, and nuclear (CBRN) incidents, pandemic influenza, COVID-19, and other emerging infectious diseases. BARDA works closely with interagency partners through the Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) to ensure a coordinated, whole-of-Government approach to MCM preparedness and response. The BARDA model has proven successful in leveraging public-private partnerships to accelerate development of MCMs that are vital to national security. BARDA helps its partners promote innovation and develop countermeasures from early research through U.S. Food and Drug Administration (FDA) approval and clinical application.

Work Details
The solicitation seeks proposals for the advanced R&D of Medical Countermeasures (MCMs) for CBRN agents, pandemic influenza, and emerging infectious diseases that threaten the U.S. civilian population. The proposal should focus on R&D in various areas of interest such as CBRN Vaccines, Antivirals, Antimicrobials, Diagnostics, and others. Offerors are required to address Program Management Approach, Regulatory Approach, Development and Manufacturing Approach in their proposals.

Period of Performance
The proposal submission deadline is September 25, 2028 at 4:30 PM Eastern Time for open areas of interest.

Place of Performance
The contract will be performed at locations determined by the U.S. Department of Health and Human Services.